Valuation : Gilead Sciences, Inc.

Market Cap 178B 154B 145B 132B 247B 17,025B 248B 1,727B 664B 8,662B 669B 655B 27,370B P/E 2026 *
-43.5x
P/E 2027 * 17.9x
Enterprise Value 195B 168B 159B 144B 270B 18,625B 272B 1,889B 726B 9,475B 732B 716B 29,941B EV / Sales 2026 *
6.35x
EV / Sales 2027 * 5.73x
Free-Float
99.88%
Yield 2026 *
2.29%
Yield 2027 * 2.33%
1 day-0.75%
1 week-4.82%
Current month-1.79%
1 month+5.78%
3 months+14.44%
6 months-1.03%
Current year+17.09%
1 week 143.5
Extreme 143.5
148.65
1 month 135.91
Extreme 135.91
152.55
Current year 116.88
Extreme 116.88
157.29
1 year 108.46
Extreme 108.4601
157.29
3 years 62.07
Extreme 62.07
157.29
5 years 57.16
Extreme 57.165
157.29
10 years 56.56
Extreme 56.56
157.29
Manager TitleAgeSince
Chief Executive Officer 61 2019-02-28
Director of Finance/CFO 56 2019-10-31
Compliance Officer - 2025-12-17
Director TitleAgeSince
Director/Board Member 58 2016-08-18
Director/Board Member 73 2017-12-31
Director/Board Member 72 2018-05-08
Date Insider Type Main position Quantity % Market Cap. Importance
9/1/26 Sell

Chief Executive Officer

-15,000 0.0012%
8/26/26 Exercice

Director

54,000 0.0043%
8/20/26 Exercice

Director

15,000 0.0012%
Change 5-day change 1-year change 3-year change Capi.($)
-0.75%-4.82%+25.46%+87.14% 178B
-0.65%-2.93%+47.70%+86.17% 994B
-0.29%-3.51%+49.15%+62.35% 640B
+0.83%+0.26%+17.76%+72.25% 454B
-0.38%-3.59%+30.13%+35.17% 337B
-0.09%-13.54%+13.34%+24.95% 261B
-0.43%-2.48%-0.73%+9.58% 246B
-1.34%-13.70%+36.53%+44.96% 204B
-3.44%-7.51%-20.63%-59.44% 190B
+0.25%-2.57%+16.13%-18.83% 158B
Average -0.63%-5.44%+21.49%+34.43% 366.28B
Weighted average by Cap. -0.47%-4.34%+30.32%+51.76%

Financials

2026 *2027 *
Net sales 30.69B 26.44B 25.04B 22.69B 42.58B 2,932B 42.79B 297B 114B 1,492B 115B 113B 4,714B 32.68B 28.16B 26.66B 24.17B 45.34B 3,122B 45.57B 317B 122B 1,589B 123B 120B 5,020B
Net income -4.27B -3.68B -3.49B -3.16B -5.93B -408B -5.96B -41.42B -15.93B -208B -16.05B -15.7B -657B 10.28B 8.85B 8.38B 7.6B 14.25B 982B 14.33B 99.56B 38.28B 499B 38.59B 37.74B 1,578B
Net Debt 16.75B 14.43B 13.66B 12.38B 23.23B 1,600B 23.35B 162B 62.39B 814B 62.89B 61.51B 2,572B 9.12B 7.86B 7.44B 6.75B 12.66B 872B 12.72B 88.41B 34B 443B 34.27B 33.52B 1,401B
Logo Gilead Sciences, Inc.
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.2%): for the treatment of HIV (71.8% of net sales), oncology diseases (11.2%), hepatitis B virus (11.1%), Ebola virus (3.2%) and other (2.7%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.8%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (70.9%), Europe (17.2%) and other (11.9%).
Employees
17,000
Date Price Change Volume
26-09-11 $143.72 -0.75% 4,202,446
26-09-10 $144.81 -0.58% 6,019,851
26-09-09 $145.65 -0.68% 4,583,213
26-09-08 $146.64 -2.88% 6,080,502
26-09-04 $151.00 -0.15% 6,181,783
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
143.72USD
Average target price
158.15USD
Spread / Average Target
+10.04%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GILD Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!